Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inebilizumab - Viela Bio

Drug Profile

Inebilizumab - Viela Bio

Alternative Names: 16C4-aFuc; A-fucosylated anti-CD19 antibody; Anti-CD19 MAb-Viela-Bio; MEDI 551

Latest Information Update: 08 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cellective Therapeutics
  • Developer MedImmune; Viela Bio
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD19 antigen inhibitors; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuromyelitis optica
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Neuromyelitis optica
  • Phase II Chronic lymphocytic leukaemia
  • Phase I/II B-cell lymphoma; Follicular lymphoma; Multiple myeloma; Multiple sclerosis
  • Phase I Autoimmune disorders; Myasthenia gravis; Renal transplant rejection
  • No development reported Systemic scleroderma
  • Discontinued Diffuse large B cell lymphoma

Most Recent Events

  • 08 Nov 2019 Phase-I clinical trials in Autoimmune disorders in USA (IV) before November 2019 (Viela Bio pipeline November 2019)
  • 08 Nov 2019 Phase-I clinical trials in Myasthenia gravis in USA (IV) before November 2019 (Viela Bio pipeline November 2019)
  • 08 Nov 2019 Phase-I clinical trials in Renal transplant rejection in USA (IV) before November 2019 (Viela Bio pipeline November 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top